Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial
NCT04375657
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Epigenetic Aging
- Immunosenescence
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Intervene Immune, Inc.
- Last updated on ClinicalTrials.gov
- May 7, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Intervene Immune · Torrance, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.